Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Refractory* status classifications for Phase 2 Post-hoc analysis

From: Understanding side effects of therapy for myasthenia gravis and their impact on daily life

 Previous use of at least two immunosuppressive treatmentsCurrent use of immunosuppressive treatmentUse of IVIg and/or plasmapheresis on more than four separate occasions over the past year
Refractory with IVIgYesYesYes
YesNoYes
NoYesYes
Refractory without IVIgYesYesNo
YesNoNo
Non-refractoryNoYesNo
  1. *Refractory = MG post-intervention status unchanged since initiation of treatment
  2. IVIg, intravenous immunoglobulin